Atea Pharmaceuticals (Atea Pharmaceuticals) Market Cap : $312.25 Mil (As of Apr. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Atea Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Atea Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $3.05. Atea Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 83.44 Mil. Therefore, Atea Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $254.48 Mil.

Atea Pharmaceuticals's quarterly market cap declined from Jun. 2023 ($311.91 Mil) to Sep. 2023 ($250.31 Mil) but then increased from Sep. 2023 ($250.31 Mil) to Dec. 2023 ($254.48 Mil).

Atea Pharmaceuticals's annual market cap declined from Dec. 2021 ($742.94 Mil) to Dec. 2022 ($400.61 Mil) and declined from Dec. 2022 ($400.61 Mil) to Dec. 2023 ($254.48 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Atea Pharmaceuticals's Enterprise Value for Today is $-263.45 Mil.

Atea Pharmaceuticals Market Cap Historical Data

The historical data trend for Atea Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atea Pharmaceuticals Market Cap Chart

Atea Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

3,444.21

742.94

400.61

254.48

Atea Pharmaceuticals Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															400.61	279.39	311.91	250.31	254.48

Competitive Comparison of Atea Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Atea Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atea Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's Market Cap falls into.

Atea Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Atea Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$3.05	*	83.4355
	=	$254.48

Atea Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$3.05	*	83.4355
	=	$254.48

Atea Pharmaceuticals (NAS:AVIR) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Atea Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Atea Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Atea Pharmaceuticals (Atea Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atea Pharmaceuticals Inc (NAS:AVIR) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

225 Franklin Street, Suite 2100, Boston, MA, USA, 02110

Website

https://www.ateapharma.com

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Executives

Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Polly A. Murphy	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Jerome M. Adams	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp	10 percent owner	190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Jean-pierre Sommadossi	director, 10 percent owner, officer: President, CEO, and Chairman	125 SUMMER STREET, 16TH FLOOR, BOSTON MA 02110
Jpm Partners Llc	10 percent owner	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Chung K. Chu	10 percent owner	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Janet Mj Hammond	officer: Chief Development Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Isaac Cheng	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
John Vavricka	officer: Chief Commercial Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruno Lucidi	director	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Maria Arantxa Horga	officer: Acting Chief Medical Officer	C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Bruce Polsky	director	C/O VISION-SCIENCES, INC., 40 RAMLAND ROAD, ORANGEBURG NY 10962